Ramachandran “TR” Thirucote, Ph.D.
Chairman & CEO
Dr. TR Thirucote is a co-founder of TesoRx and has served as CEO from its inception in 2010. He has 30 years of experience in the design, development and launch of several products that included tablets, capsules, injectable and oral dosage forms, ointments, creams and nasal drug delivery systems.
Prior to establishing TesoRx, TR held senior positions at ROXRO Pharma, where he was primarily responsible for developing SPRIX™, SRI (formerly Stanford Research Institute) International, Agouron Pharmaceuticals (now Pfizer), Thermedics and Astra-IDL. He is a well-known and published scientist, having authored numerous patents and speaks regularly at national and international symposia. He is an active participant/consultant to the US National Institute of Health (NIH) and a member of the Special Emphasis Review Panel for the National Institute of Allergy and Infectious Diseases (NIAID).
Michael G Oefelein MD, FACS
Chief Medical Officer
Dr. Michael Oefelein joined TesoRx as Chief Medical Officer in 2014. He is a board certified physician and a Fellow of the American College of Surgeons with extensive experience in academia, private practice and pharmaceutical and the device industries, including dermatology, urology, oncology, ophthalmology and plastic and bariatric surgery.
Prior to joining TesoRx, Michael held various senior pharmaceutical company positions, including CMO at Digirad, Vice President and Global Therapeutic Area Head at Allergan Medical, and worked as assistant professor of Urology and Oncology at Ireland Cancer Center-Case Western Reserve University. He designed and executed clinical trials and helped develop several genitourinary oncology drugs: Degarelix, Zometa and Apaziquone, and non-oncology drugs: Levaquin, Botox, Serenity-120, and devices: Seriscaffold, Breast implants, HA-fillers and surgical navigations systems. He has also led several device (Silicone breast implants, Lap-Band) and pharmaceutical (Bimatoprost, Latisse, Sanctura XR) safety evaluations.
Michael is an active member of numerous medical societies, including the Society of Urological Oncology, SUFU, AUA, American College of Surgeons and Laparoscopic surgeons. As a senior key opinion leader, he has led numerous advisory board meetings, authored nearly 100 peer reviewed publications, delivered several scientific presentations and developed numerous publication and differentiation plans for a wide range of pharmaceutical and device assets.
Guru Betageri, Ph.D.
Chief Scientific Advisor
Dr. Guru Betageri is a co-founder of TesoRx and the inventor of its proprietary drug delivery system. He has served as Chief Scientific Advisor since its inception when TesoRx secured an exclusive license to the technology from Western University of Health Sciences in Pomona, California (WesternU).
Guru is an AAPS Fellow and a leading expert in the area of liposome, proliposome and lipid based drug delivery systems. As Associate Provost for Graduate Studies at WesternU, he currently teaches pre-formulation, product development and novel drug delivery systems to graduate students. He also conducts research work supported by federal agencies as well as numerous pharmaceutical companies, especially in the area of solid dosage forms, and has been instrumental in the formulation and development of several products now on the market.
Guru has published more than 80 original research papers in refereed journals, presented more than 150 papers at national and international meetings and is the co-author of the book “Liposome Drug Delivery” as well as several chapters of other books. He is a frequent speaker at national and international conferences and pharmaceutical companies and has authored numerous US patents. He is a reviewer or member of the editorial board for more than 12 pharmaceutical journals and still a prolific scientist.
Willem A Robberts C.A. (SA), M.Comm(RAU)
President & CFO
Mr. Willem Robberts is a co-founder of TesoRx and has served as President and CFO from its inception. He has 23 years of senior executive experience in life sciences, software and technology. As a senior level executive he has led companies in software, technology and professional services and executed numerous M&A transactions.
Prior to establishing TesoRx, Will was Executive Vice President at a legal services company called Esquire, Vice President at Thomson Reuters and President of LiveNote, which he sold in 2006. Before that, Will was the President of Accountmate and CFO for the North American operations of Softline Ltd. He started his career with KPMG Corporate Finance in London and Johannesburg where he managed numerous public and private acquisitions, disposals and investment rounds in the technology and media sectors.
Shigeo Horie M.D., Ph.D.
Dr. Shigeo Horie is professor and chairman of Juntendo University Graduate School of Medicine. Shigeo is a key opinion leader in urology and oncology and has served as a TesoRx special advisor since 2016. He graduated from the University of Tokyo in 1985 and did his research and clinical fellowship at the UT Southwestern medical center in Dallas. Shigeo joined the faculty of the University of Tokyo, National Cancer Center Hospital, and Kyorin University before becoming the chairman of the Department of Urology of Teikyo University in 2003.
In 2012, Shigeo was appointed as the chairman of the Department of Urology of Juntendo University. He specialized in uro-oncology, urinary dysfunction, and Men’s Health and is considered the leading robotic surgeon in Asia. He published more than 150 peer-reviewed papers.